Depo-Provera can lower bone mineral density (BMD)—the concern behind searches for “depo provera bone density”—but the US two-year warning is not an automatic instruction to stop. Bone density often improves after stopping, while whether Depo-Provera increases the chance of fractures later in life remains uncertain. Your age, bone-health risks and need for reliable contraception all matter when weighing what to do.
What Depo Provera Bone Density Changes Mean
Depo-Provera is an injection of depot medroxyprogesterone acetate (DMPA), usually given every three months. DMPA suppresses ovarian estrogen production, which can contribute to bone loss. Studies link its use with reduced BMD; loss tends to be greater with longer use, although it may slow after the first years.
BMD is a measure of bone mass, not a fracture. A lower reading does not, by itself, show that you will break a bone. The important unanswered question is whether changes during DMPA use lead to more fractures years later. The American College of Obstetricians and Gynecologists (ACOG) says high-quality data do not answer that question for adolescents or adults.
Recovery After Stopping: Reassuring, But Not a Guarantee
Evidence indicates that BMD generally rises after DMPA is discontinued, but recovery may be partial or complete and can vary by bone site and by what contraception you use next. It is not accurate to promise that every person will return fully to their previous level.
In a study by Abbey B. Berenson and colleagues, 703 white, Black and Hispanic women aged 16–33 chose DMPA, oral contraception or nonhormonal contraception. Researchers measured BMD every six months for up to three years; they also followed 68 women after they stopped DMPA. After discontinuing, women who chose nonhormonal contraception gained BMD at the spine and femoral neck. Those who chose oral contraception regained BMD at the spine, but not at the femoral neck during the follow-up. These results describe a particular group of young women and a limited follow-up period; they cannot predict an individual’s recovery.
A 2025 rapid review by Blake Erhardt-Ohren, Ndola Prata and Scott Rosenblum brought together 32 research items, most focused on the 150 mg intramuscular injection. The authors found a clear association with BMD loss and evidence of partial or complete recovery after stopping, while noting that restoration and bone-health treatment during use are not adequately researched. The review also found bone loss appeared more common among younger users. This supports taking age into account, but it does not establish a personal outcome or a fracture risk.
Why the US Two-Year Warning Differs From ACOG Guidance
The US FDA-approved Depo-Provera CI label warns that bone loss may not be fully reversible and says the injection should not be used as long-term birth control beyond two years unless other methods are inadequate. It also notes uncertainty about whether use during adolescence or early adulthood affects peak bone mass and later fracture risk.
ACOG’s Committee Opinion No. 602 takes a different clinical approach: it says concern about bone effects alone should not prevent prescribing DMPA or continuing it beyond two years. Instead, clinicians should weigh bone-health concerns against the likelihood and consequences of pregnancy with another method—or no method—and discuss the FDA warning with patients. The label is a US regulatory warning; European product information for Sayana Press also flags BMD, particularly for adolescents, but that does not establish an identical two-year rule for every country or formulation. Ask which product information and local guidance apply where you receive care.
Age And Personal Risk Belong In The Conversation
Adolescence and early adulthood are important years for building bone, so a possible effect on peak bone mass deserves particular attention. That does not mean every younger person must avoid DMPA. Nor does age alone capture your risk. Smoking, low body weight, a family history of osteoporosis, low calcium intake, chronic illness and some medicines can also matter for bone health.
Tell your clinician about any history of fractures, osteoporosis risks, relevant conditions or medicines. These details can help shape a discussion about whether DMPA remains a good fit and whether a bone assessment is appropriate. Bone-density scanning is not automatically needed for every person using DMPA; screening decisions depend on individual circumstances.
Plan A Change Rather Than Stopping Abruptly
If you want to stop or switch, talk with a clinician before your next injection is due. You can compare other contraceptive options, how well they match your preferences and health needs, and how to avoid a gap in pregnancy protection. ACOG’s guidance emphasizes that the decision is a balance—not a fixed deadline for everyone. Don’t stop contraception abruptly without a plan if you want to avoid pregnancy. If you have a fracture or a condition that affects bone health, ask your clinician for advice tailored to your situation.